Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
about
Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adultsThe concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A.Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillanceImmune tolerance therapy in patients with acquired hemophilia.Immunological aspects of inhibitor development.Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?Innovating immune tolerance induction for haemophilia.Acquired haemophilia and its management.Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisoneAcquired haemophilia: experiences with a standardized approach.Polystyrene derivatives as candidates for extracorporeal adsorption of Factor VIII antibodies in the management of haemophiliac patients.A case of acquired haemophilia A complicated by peritonitis after distal gastrectomy.In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus.A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.IgG subclasses of FVIII inhibitors in an argentine cohort of severe hemophilia A patients: Analysis by flow cytometry.Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay.Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals.Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient.Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.Maternal anti-protein Z antibodies in pregnancies complicated by pre-eclampsia, SGA and fetal death
P2860
Q34189547-4B37D8CF-A6DF-4207-ACB9-2C4E1B4054EFQ34384371-3ED50283-A4A5-4936-B68B-9A45254CB675Q34609618-EAE916D1-3986-4612-84C7-DC8551ABFDE2Q34636981-D43DBC9B-82A0-4EF7-91CA-EE46831BD8DEQ35770805-1B00C425-1D40-4D2B-99E8-A39ED55A5AE8Q35994817-31344D28-26D9-474F-983F-4B3752AF94B4Q36661819-F6B0F448-50EE-4D8F-8550-6BADF96EC47FQ37944291-0470D482-AE38-4607-8BAC-A4954B540502Q38894155-23A6A3E2-9444-4A3A-BC1C-B9E798B9F5DAQ40602765-78241C6E-9CC1-4B28-B993-1A72DB1CA3FCQ41185091-775981B9-DA39-4CDD-A205-6F277F10FC24Q43548829-D762D362-B9E5-4445-9EC7-DC0E2EAE8820Q45855307-FEDA77B6-35D2-4915-BA01-1FB9AB75022FQ45856776-A3E254AF-CC82-46EB-BC1F-E1BA00813A11Q45857166-B09DA2CC-DD29-40F1-A87E-EF4620DC4DA6Q45859666-B31BA1FA-EA3D-42C2-8C5F-71185A3ABB6DQ45863101-6258331A-D663-4716-8D64-5EBDE0AE7B94Q45864882-5F82BEEC-25CF-48E1-A727-53154B863313Q45868089-7B407802-4375-422D-A7F1-C79F35298FAFQ45868834-C5C2979F-9B38-4F29-AEDC-308153762F78Q45873659-2C28C9FD-2ACF-48EB-AC13-708E5CD292FCQ45876857-A5AA7330-88F3-4A79-B69A-CFAFEBD0078FQ45883602-30296819-C01A-4AD9-9C23-BBF2DAE173CEQ45886534-9FF6D343-7458-4B0B-BF27-4551D20622CAQ48251548-162F4AA5-A4F7-4206-B932-DEEF93EF3AC0Q53695989-245A03B8-730A-4C85-ABFF-A1C7DA533AC7Q58417749-89F66C18-CCAD-4C5C-8575-7576E0700EC4
P2860
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
@en
Natural antibodies to factor VIII
@nl
type
label
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
@en
Natural antibodies to factor VIII
@nl
prefLabel
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
@en
Natural antibodies to factor VIII
@nl
P2093
P2860
P921
P356
P1476
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
@en
P2093
Boieldieu D
Dietrich G
Kazatchkine MD
Nydegger UE
P2860
P304
P356
10.1073/PNAS.89.9.3795
P407
P577
1992-05-01T00:00:00Z